Introduction

A 35 years old lady was admitted to the medical assessment Unit with 2 weeks of progressive breathlessness and distended abdomen. On examination she did have a large right pleural effusion and very large distended abdomen.

Blood test including FBC, U&E, LFT and calcium were normal with a CRP of 33. She underwent a CT abdomen which demonstrated a very large mass in the abdomen, multicystic, suggestive of ovarian origin (Figure 1). The uterus was bulky, and there was a large right pleural effusion.

The pleural effusion was drained and under gynaecologist she did have surgery: total hysterectomy, bilateral salpingo-oopherectomy, omentectomy and peritoneal washing for a large 40-50cm multiloculated tumour.

Histology demonstrated a stage 1c grade 2 endometrioid ovarian adenocarcinoma and stage 1a endometrial carcinoma. Oncologist advised to add adjuvant chemotherapy to her treatment with Carboplatin and Paclitaxel. She moved to Fiji after her relative's death and not follow up has been possible.

Ovarian cysts can vary in size, from <1cm to >10cm. A large cyst does not predict if cancer is present.

Endometrioid ovarian cancer represents a 10-15% of primary ovarian tumors. 15% coexists with endometriosis. 15-30% of patients will have synchronous endometrial hyperplasia or carcinoma. This 2 types of cancer share many histological and molecular alterations, likely due to a common endometrial epithelial precursor cell of origin [1].

Endometriosis is thought to occur via retrograde menstruation, and the endometrial cells settle as an endometriotic cyst within the ovary. The menstruation like blood and necrotic tissue is trapped in the cyst causing oxidative stress and hypoxic environment leading to DNA damage and mutation accumulation.
Women with endometrioid cancer present at a younger age and with earlier stage disease than those with serous ovarian cancer [2,3]. The endometrioid histology is associated with better survival rates than in serous adenocarcinoma of the ovary, and is correlated with earlier presentation. Patients with concurrent endometrioid ovarian and endometrial malignancies had a survival advantage compared with those with ovarian malignancies alone [2].

References